Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation
The injuries linked to Philips recalled devices primarily stem from the degradation of PE-PUR foam used in the devices, which releases particulate matter and toxic chemicals when broken down. Inhalation or ingestion of these substances can cause respiratory inflammation, lung injury, and potentially carcinogenic effects. Scientific studies, including a 2025 publication, have documented cases of interstitial lung disease and other respiratory symptoms associated with foam particle inhalation, supported by FDA safety communications and Philips' testing data ([PMC.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12088699), [FDA.gov](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/philips-issues-recall-notification-mitigate-potential-health-risks-related-sound-abatement-foam)). The mechanism involves chemical exposure and particulate inhalation, with risk factors including device age, exposure to ozone cleaning agents, and environmental conditions that accelerate foam degradation.
623
Pending actions
1,032
Total actions filed
Active
Status
10/08/2021
Established
Filing deadline
Claims submission deadline was February 7, 2024, with objections due by November 23, 2023. Final settlement approval occurred in April 2024, with ongoing claims processing.
Who qualifies
Plaintiffs qualify if they used the recalled Philips devices, such as CPAP, Bi-Level PAP, or ventilators, between the device's manufacture date and the recall date, and subsequently developed injuries such as respiratory impairment, lung disease, or cancer. Medical documentation confirming diagnosis, device usage, and exposure duration is required. The injury must be linked to foam degradation products, with evidence of inhalation or ingestion of degraded foam particles. The court's pretrial orders specify submission of detailed medical and usage histories, and claims are evaluated based on injury severity, with higher compensation for severe injuries like cancer or respiratory failure.
Products involved
- A-Series BiPAP A30
- A-Series BiPAP A40 (ventilator)
- A-Series BiPAP Hybrid A30
- A-Series BiPAP V30 Auto (ventilator)
- C-Series ASV (ventilator)
- C-Series S/T and AVAPS
- DreamStation
- DreamStation ASV
- DreamStation Go
- DreamStation ST, AVAPS
- Dorma 400
- Dorma 500
- E30
- Garbin Plus, Aeris, LifeVent (ventilator)
- OmniLab Advanced+
- REMstar SE Auto
- SystemOne ASV4
- SystemOne (Q-Series)
- Trilogy 100 (ventilator)
- Trilogy 200 (ventilator)
Alleged injuries
- Respiratory impairment
- Lung injury
- Asthma exacerbation
- Interstitial lung disease
- Cancer (lung, other)
- Headaches and irritation
Bellwether trials
Bellwether trials are scheduled for 2026, with some trials expected to begin in that year. The court has managed multiple pretrial proceedings, and recent rulings include settlement approvals and ongoing case management. No specific verdicts are publicly reported yet, but the process is active and progressing.
Settlement landscape
The overall settlement amount is approximately $1.1 billion, with potential liabilities reaching up to $4.5 billion. Settlement tiers are based on injury severity, with compensation ranging from $50,000 to over $500,000 for severe injuries such as cancer or respiratory failure. The settlement involves multiple funds, including User and Payer Settlement Funds, with payouts determined by injury severity and documentation. The court approved the settlement in April 2024, and claims are being processed with ongoing disbursements.
Lead counsel
- Levin Sedran & Berman
- Lynch Carpenter
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
